Latest Diabetes News
Study points to need for better coordinated care, more effective use of medications.
Those with type 2 diabetes and heart disease as well as a prior cardiovascular event have an increased risk of cardiovascular mortality.
Odds of cardiovascular mortality 14.8% higher in black Americans with both conditions.
For patients taking metformin, TZD and DPP-4i linked to lower mortality, cardiovascular risks.
In a study of patients who had been prescribed long-acting opioid medications, 185 patients in the opioid group died.
The Food and Drug Administration (FDA) announced it is strengthening the current warning about the risk of acute kidney injury for drug products containing canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR).
Incident or worsening nephropathy was observed in 12.7% of patients receiving empagliflozin compared with 18.8% of those receiving placebo.
Length of time spent in remission inversely related to risk of microvascular disease.
There was also a 22% reduction in the development of renal outcomes with liraglutide compared to placebo.
Sulfonylureas therapy in addition to metformin maintains glycemic control but does not change body weight in patients with type 2 diabetes.
Patients exposed to high levels of air pollution have an elevated risk of cardiovascular disease.
High vs. low fitness levels in midlife lowered CKD risk in later life by 34%.
Findings for clinically complex patients with type 2 diabetes.
The finding is from a 30-week study comparing testosterone undecanoate and placebo in hypogonadal men with type 2 diabetes.
Increased risk for cardiovascular events and all-cause mortality for patients with type 2 diabetes.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)